Wiener Gesundheitsverbund

At Wiener Gesundheitsverbund in Vienna, the Department of Respiratory and Pulmonary Diseases is conducting clinical research focused on cancer affecting the lungs, with an emphasis on improving treatment options for small-cell lung cancer and non-small cell lung cancer. These studies are designed to evaluate whether new therapy combinations can improve survival and disease control for people with advanced disease.

• Extensive-stage small-cell lung cancer: comparing a new treatment approach with an established cancer therapy to assess overall survival.
• c-Met overexpressing, EGFR wildtype non-squamous non-small cell lung cancer: testing a targeted therapy against a standard chemotherapy option.

The research highlights the site’s role in advancing oncology care through studies that aim to better understand treatment effectiveness and expand options for patients with hard-to-treat lung cancers.

This hospital-based research program in Vienna is centered on patients with lung malignancies, linking respiratory medicine with modern oncology research. The trials are exploring whether targeted and immunotherapy-based approaches can offer better outcomes than current treatment standards.

• Evaluation of a new combination treatment for extensive-stage small-cell lung cancer to improve survival outcomes.
• Assessment of telisotuzumab vedotin versus docetaxel in previously treated non-squamous non-small cell lung cancer to measure disease activity and treatment benefit.

With a small but focused portfolio of trials, the site contributes to research aimed at refining diagnostics and treatment strategies for lung cancer subtypes linked to c-Met expression.